Cargando…

Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic

INTRODUCTION: During the pandemic, smokers who wished to access support to quit faced additional barriers. A smoking cessation service which utilized pharmacist independent prescribers working within community pharmacy was implemented. Clients received behavioral advice via a consultation with an ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Trudy, Sykes, Bronte, Shah, Shilpa, Corlett, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603824/
https://www.ncbi.nlm.nih.gov/pubmed/37901881
http://dx.doi.org/10.18332/tid/170580
_version_ 1785126687972786176
author Thomas, Trudy
Sykes, Bronte
Shah, Shilpa
Corlett, Sarah
author_facet Thomas, Trudy
Sykes, Bronte
Shah, Shilpa
Corlett, Sarah
author_sort Thomas, Trudy
collection PubMed
description INTRODUCTION: During the pandemic, smokers who wished to access support to quit faced additional barriers. A smoking cessation service which utilized pharmacist independent prescribers working within community pharmacy was implemented. Clients received behavioral advice via a consultation with an advisor and then three consultations with a pharmacist, who prescribed varenicline, where appropriate. Consultations were by phone or video. This evaluation assessed the self-reported outcomes and experiences of clients and pharmacists. METHODS: A mixed-methods approach was used involving both on-line questionnaires to clients and interviews with a sample of questionnaire respondents and participating prescribing pharmacists. RESULTS: The questionnaire was completed by 85 clients with 59% reporting they had quit. Eleven clients and seven out of eight pharmacists were interviewed. Varenicline had been received by 96% of clients. The best aspects of the service reported by clients in the questionnaire and at interview were support received from the pharmacist and ease of access to varenicline. Clients regarded the service as being ‘safe’ to access during the pandemic. Nearly three-quarters of client respondents (72%) stated no service improvements were required. However, national supply challenges made collection of varenicline from the nominated pharmacy an issue. Some clients experienced a long wait-time before accessing the service. For pharmacists, the service offered flexibility including the opportunity to contact clients ‘out of office’ hours without distractions. However, not being physically in the pharmacy could result in them not being able to access the client’s medicine history. Pharmacists identified that remote consultations were not ideal for all clients. CONCLUSIONS: Pharmacist prescribers can deliver effective smoking cessation services through remote consultations. Greater flexibility would allow the service to be tailored to the client’s need.
format Online
Article
Text
id pubmed-10603824
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID)
record_format MEDLINE/PubMed
spelling pubmed-106038242023-10-28 Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic Thomas, Trudy Sykes, Bronte Shah, Shilpa Corlett, Sarah Tob Induc Dis Research Paper INTRODUCTION: During the pandemic, smokers who wished to access support to quit faced additional barriers. A smoking cessation service which utilized pharmacist independent prescribers working within community pharmacy was implemented. Clients received behavioral advice via a consultation with an advisor and then three consultations with a pharmacist, who prescribed varenicline, where appropriate. Consultations were by phone or video. This evaluation assessed the self-reported outcomes and experiences of clients and pharmacists. METHODS: A mixed-methods approach was used involving both on-line questionnaires to clients and interviews with a sample of questionnaire respondents and participating prescribing pharmacists. RESULTS: The questionnaire was completed by 85 clients with 59% reporting they had quit. Eleven clients and seven out of eight pharmacists were interviewed. Varenicline had been received by 96% of clients. The best aspects of the service reported by clients in the questionnaire and at interview were support received from the pharmacist and ease of access to varenicline. Clients regarded the service as being ‘safe’ to access during the pandemic. Nearly three-quarters of client respondents (72%) stated no service improvements were required. However, national supply challenges made collection of varenicline from the nominated pharmacy an issue. Some clients experienced a long wait-time before accessing the service. For pharmacists, the service offered flexibility including the opportunity to contact clients ‘out of office’ hours without distractions. However, not being physically in the pharmacy could result in them not being able to access the client’s medicine history. Pharmacists identified that remote consultations were not ideal for all clients. CONCLUSIONS: Pharmacist prescribers can deliver effective smoking cessation services through remote consultations. Greater flexibility would allow the service to be tailored to the client’s need. European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) 2023-10-27 /pmc/articles/PMC10603824/ /pubmed/37901881 http://dx.doi.org/10.18332/tid/170580 Text en © 2023 Thomas T. et al. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License.
spellingShingle Research Paper
Thomas, Trudy
Sykes, Bronte
Shah, Shilpa
Corlett, Sarah
Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
title Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
title_full Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
title_fullStr Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
title_full_unstemmed Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
title_short Pharmacist prescriber smoking cessation intervention during the COVID-19 pandemic
title_sort pharmacist prescriber smoking cessation intervention during the covid-19 pandemic
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603824/
https://www.ncbi.nlm.nih.gov/pubmed/37901881
http://dx.doi.org/10.18332/tid/170580
work_keys_str_mv AT thomastrudy pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic
AT sykesbronte pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic
AT shahshilpa pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic
AT corlettsarah pharmacistprescribersmokingcessationinterventionduringthecovid19pandemic